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The immunological and clinical parameters that are associated with asthma remission are poorly understood. The
cytokine and local mediator changes associated with the resolution of asthma symptoms were examined in three
groups of subjects 12–18 years of age (n = 15 in each group): (a) continuing asthma group (CA) who had persistent
symptoms since early childhood, (b) an age, sex and atopic status-matched group who had persistent symptoms in
early childhood but in whom these had resolved (RA), and (c) a non-atopic, non-asthmatic control group. Clinical
parameters, sputum cell counts, peripheral blood mononuclear cell (PBMC) cytokine production and activation
marker expression were determined. All of the CA had methacholine airway hyperresponsiveness compared with
only half of the RA subjects. The CA showed elevated numbers of eosinophils and increased ECP and IL-5 in
sputum, which were not observed in the RA. PBMC cytokine studies revealed increased production of the type 1
cytokines IL-12, IFN-γ and TNF-α in the CA group compared with the RA group, under a range of activation
conditions, however, the production of IL-4 and IL-5 were unchanged. These findings suggest that decreased type
1 cytokine expression as well as decreased eosinophilic inflammation is associated with the resolution of asthma
symptoms.
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Asthma is characterized by episodic symptoms of
wheeze, breathlessness or chest tightness due to variable
airflow obstruction and increased airway responsiveness
that may or may not be associated with bronchitis. The
prevalence has been estimated at 10-20% in children
[1,2]. Wheezing is more likely to persist and develop into
asthma in children with atopy, a positive family history,
(especially maternal) of asthma or atopy, airway hyperre-
sponsiveness, and exposure to indoor allergens or
cigarette smoke [3-11]. Wheezing associated with the
development of asthma tends to begin at age 3 or per-
sists beyond this age [12].* Correspondence: waserman@mcmaster.ca
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distribution, and reproduction in any mediumIndications of a predisposition to asthma are often
present early in life, possibly even before birth [13-15].
Although atopy may be evident in early infancy, the gen-
eration of pulmonary responses appears to require local
sensitization of the airways to aeroallergens, a process
that may require allergen exposure for 2–3 years. By age
3, atopic children with recurrent wheezing illnesses ex-
hibit increased mast cell and eosinophil numbers in lav-
age fluid [12]. Upon exposure to allergen, sensitive
individuals will respond with rapid mast cell degranula-
tion and activation of antigen presentation, and the re-
cruitment of effector cells such as T cells and
eosinophils. This inflammatory response may become
chronic, if allergen exposure is not terminated or if ap-
propriate treatment is not administered. Indeed, chron-
ically activated memory T cells are observed in asthma
[16], with an enhanced capacity to produce IL-4 and
IFN-γ [17,18]. During this consolidation phase, struc-
tural damage due to persistent inflammation results intral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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airflow limitation and possibly greater hyperresponsive-
ness [19-24].
A proportion of children with asthma will “outgrow”
their disease, and become symptom-free as adults,
[5,7,25] even though many of them remain hyperrespon-
sive [10]. A number of factors have been associated with
the persistence of asthma into adulthood, including fe-
male gender, increased severity of symptoms in child-
hood, high serum IgE, low FEV1 or PC20, and those
with perennial symptoms in response to house dust mite
or molds [8-10,20]. While these correlations have been
made, there is little understanding of the immunological
mechanisms by which asthma develops into a persistent
disease, or by which symptoms regress.
Expression of cytokines can profoundly influence im-
munological processes. Allergic diseases are critically
dependent upon the development of Th2 cells, especially
as a source of IL-4 which is critical for IgE antibody pro-
duction. T-helper cell differentiation is influenced by the
strength of T-cell receptor MHC interaction and the na-
ture of co-stimulation, but most importantly by the pres-
ence of IL-12, which promotes Th1 differentiation, IL-4,
which promotes Th2 differentiation, and IFN-γ, which
tends to antagonize the development of Th2 cells. Acti-
vated Th2 cells are prolific sources of IL-4, IL-5, and IL-
13, among other cytokines, each of which has been sug-
gested to play a role in asthma pathogenesis. Peripheral
blood mononuclear cells (PBMCs) from asthmatic and
atopic patients have been shown to produce Th2-
associated cytokines upon stimulation with allergen,
[17,26-29], non-specific stimuli such as PMA or anti-
CD3 [27,28,30] and in the absence of experimental
stimulation [31]. Type 1 cytokines such as TNF-α, IL-12
and IFN-γ have a pivotal role in enhancing the infiltra-
tion and activation of effector cells in host defence and
many inflammatory diseases, and may also play an im-
portant role in asthma pathogenesis.
The objective of this study was to investigate the clin-
ical and immunological parameters which may be asso-
ciated with resolution of asthma symptoms. Adolescent
subjects with continuous asthma, those in whom child-
hood asthma symptoms had resolved and non-atopic
controls were compared with respect to a number of cri-
teria including: inflammatory cell content of the sputum,
cytokines in sputum and cytokine production by periph-
eral blood mononuclear cells (PBMC) and the proportions
of peripheral blood T cell subsets and activation markers.
Methods
Subject selection
Three groups of subjects were examined in parallel tri-
plets (one from each group). Each triplet group was
matched for age (within 1 year) and sex. Since growingout of asthma is reported to be more likely in children
with mild or no allergy we endeavoured to match group
1 and 2 for similar levels of positive skin tests using a
panel of 14 common inhalant allergens.
Resolution of asthma symptoms group (RA)
Fifteen children were recruited who had a history of at
least one year of persistent symptoms consistent with
asthma between the ages of 2–6 years inclusive who
were now aged between 12–18 years inclusive, and had
been completely and continuously free of asthma symp-
toms for at least one year. They were identified by ques-
tionnaire/ interview and examination of medical records.
Persistent asthma at ages 2–6 was necessarily defined
based on symptoms (ie. cough, wheeze, breathlessness)
considered to need asthma treatment including inhaled/
oral corticosteroids, inhaled/oral bronchodilators, theo-
phyllines, or cromolyn . The absence of asthma symp-
toms between the ages of 12–18 years was determined
from a questionnaire which included no asthma symp-
toms during vigorous exercise or respiratory infection,
and no need for asthma medication during the past year.
A cough was permitted provided it was limited to throat
clearing or less than five coughs per day in the last month.
Continuous asthma group (CA)
Fifteen children aged 12–18 years inclusive were
recruited with at least one year of persistent symptoms
consistent with asthma between the ages of 2–6 inclu-
sive and who now had persistent asthma. Persistent
asthma (ages 2–6) was defined in the same way as for
the RA. Its continued presence was confirmed by airway
hyperresponsiveness to methacholine (PC20 < 8 mg) or
an improvement in FEV1≥ 15% from baseline measure-
ment 15 minutes after receiving 200 μg of Salbutamol in
addition to daily symptoms and the need for asthma
medication.
Non atopic asymptomatic group (Control)
Fifteen subjects ages 12–18 who had no past or current
history of allergy or excessive respiratory symptoms and
who had completely negative allergy skin tests.
All subjects were required to have an FEV1 of > 70%
predicted. None of the subjects had eczema, active rhin-
itis requiring nasal steroid therapy, were past or current
smokers, were pregnant, had a chest infection within the
past month or had received allergen immunotherapy. All
study assessments were made outside the seasonal al-
lergy season, and children were instructed to try and
keep their perennial allergen exposure constant through
the assessment period. The study was approved by the
St Josephs Healthcare Research Ethics Board and written
informed consent was obtained from both subjects and
parent/guardian.
Figure 1 Blood Cell Phenotypes defined for analysis of flow
cytometric data. Major lymphocyte subsets are reported as % of
total lymphocytes. Activated or functional lymphocyte subsets are
reported as % of each lymphocyte type. Expression of functional B
or monocyte surface markers are reported as median fluorescence
intensity.
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This was a cross sectional study with two visits within
3 weeks. In visit 1, all subjects completed clinical ques-
tionnaires, provided informed consent, underwent a
physical examination and had allergy skin tests. At this
time, subjects also performed a methacholine inhalation
test, had a urine test for pregnancy (where applicable)
and subjects in the CA group were provided with salme-
terol and salbutamol. At visit 2, spirometry was per-
formed including bronchodilator reversibility, sputum
and blood samples were taken for multiple analyses (see
below). Remaining salmeterol and salbutamol were col-
lected from subjects in the CA group.
Inhaled corticosteroid medication was discontinued in
the CA group 2 weeks prior to subject testing and sam-
ple collection. At the time inhaled steroid was discontin-
ued, 2 puffs bid salmeterol was provided. Forty eight
hours before samples were taken, salmeterol was
stopped and substituted with salbutamol 2 inhalations
qid. Salbutamol was stopped at least 6 hours before
blood samples were taken. Laboratory testing was per-
formed simultaneously on three (matched) subjects, one
from each group. Laboratory personnel performing the
tests were not informed of the groups to which each
subject belonged.
Procedures
Routine physical examination, questionnaire and clinical
tests were performed according to standard protocols.
Spirometry included measurement of FVC, FEV1, FEV1/
VC and methacholine challenge tests. Blood counts
included a manual eosinophil count.
Sputum cell induction and examination
Sputum was induced with an aerosol of inhaled hyper-
tonic saline by a modification of the method of Pin et al.
[32] after pretreatment with inhaled Salbutamol 200 μg.
The modification consisted of inhaling the hypertonic
saline in concentrations of 3, 4 and 5% each for 7 min-
utes. Sputum examination followed the method of Pizzi-
chini et al. [33]. Sputum mediator assessments were
performed using routine protocols. The concentration of
eosinophil cationic protein (ECP) was determined using
a sensitive radioimmunoassay (Kabi-Pharmacia Diagnos-
tics AB, Uppsala, Sweden). Fibrinogen was measured
using an “in house” ELISA assay which employed rabbit
anti-fibrinogen antibody (Dako# A080). Cytokines were
assayed by ELISA (IL-5 using Biotrak kit, Amersham,
UK and TNF-α by “in house” ELISA).
Peripheral blood cytokine analysis
Peripheral blood mononuclear cells (PBMC) were iso-
lated from the blood of each subject. Matched triplets
which included one subject from each group weresampled and assayed in parallel. Short term cultures of
PBMC were established for 24 or 72 hours in the pres-
ence or absence of a series of stimulants. These included
anti-CD3 antibody 1 μg/ml (OKT3, Cedarlane , Burling-
ton, Ont), killed Staphylococcus aureus Cowan strain 1
bacteria (SAC) 0.07% w/v (Sigma, St Louis, Mo). E-coli
derived LPS (Sigma) 5 μg/ml, Tetanus toxoid (0.1 μg/ml)
and a combination of phorbol ester PDBu (Sigma)
(10-6 M) and Calcium ionophore A23187 (Sigma)
(10-7 M). The concentrations and timing of these stim-
uli were selected on the basis of pilot experiments.
The cytokine content of cell free supernatants, was
assessed using ELISA kits with the exception of TNF-α
which was assessed using a well validated “in house”
ELISA. The cytokine kits employed were: IL-4- Biotrak
RPN 2753, IL-5- Biotrak RPN2761, IL-6 Biotrak RPN
2754, IL-10 Biotrak RPN 2755, IL-12- Biotrak RPN
2765, GM-CSF Biotrak RPN 2757. All of these kits were
obtained from Amersham (Toronto, ON, Canada).Flow cytometric protocols and analysis
Panels of antibodies were employed in 2 and 3 colour ana-
lysis protocols to identify and calculate frequencies of T-
cell subsets, B cells, monocytes and subsets of these cells
expressing important functional markers. A complete
listing of B and T lymphocyte, and monocyte phenotypes
analysed by flow cytometry are listed in Figure 1. All
staining was done in whole blood with subsequent fixation
and wash. Flourescent labelled antibodies against CD3,
CD4, CD8, CD14, HLADR, CD45RO CD45RA, CD40
and CD23 were purchased from Becton Dickinson
Canada (Mississuaga., Ontario). Antibody to CD40 ligand
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(Mississuaga, Ont).
Statistical analysis
Non parametric statistics were used to test for differ-
ences between the subject groups. Two sets of analyses
were conducted, one testing for differences among the
three subject groups (RA vs CA vs control) and one test-
ing for diffrences between the two asthma groups ( RA
vs CA). Between group differences were for each param-
eter of interest with statistical significae for all tests set
at p = 0.05. Three way comparisons were tested using
the Friedman test, the non-parametric equivalent of
repeated measures ANOVA. Two way comparisons were
tested using the Wilcoxon signed Ranks test, the non-
parametric equivalent of the paired t-test. These provided
conservative tests of between subject group differences.
Results
Clinical evaluation and spirometry
The subjects had a median age of 15, they included 10
sets of three matched female subjects and 5 sets of three
matched male subjects. All subjects were examined in
visit 1 and 2 as originally scheduled and described above
with all asthmatic subjects completing a full 2 weeks
without inhaled corticosteroid therapy. There were no
significant differences between the subject groups for
CBC, differential blood counts (Table 1) or ESR (data
not shown).
Methacholine challenge test
The CA subjects had a mean PC20 of 1.6 mg/ml. In con-
trast, control subjects had a mean PC20 of 17.09 mg/ml
(all subjects had PC20 methacholine > 8 mg/ml). Eight out
of fifteen RA subjects had a PC20 of less than 8 mg/ml
while the rest of the subjects fell within the normal range
(Table 1). None of the RA subjects displayed any asthma
symptoms however and there was no clear relationshipTable 1 Clinical characteristics
Parameters Controls CA RA
Age 14 (12–18) 14 (13–18) 15 (12–18)
Gender (males), n 10 11 11
FEV1 3.8 (2.2-5.2) 2.8 (1.9-3.8) 3.7 (2.1-5.1)
FEV1,% 101 (88–120) 85.1 (62–105) 99 (70–123)
FEV1/VC 94 (84–112) 69.4 (50–93) 82.5 (58–100)
FEV1 reversibility 4 (0–11) 11 (0–45) 3.8 (0–8)
PC20 16 (8–32) 0.85 (0.1-6.4) 9.1 (0.5-30)
Skin prick test 0 (by definition) 7 (3–14) 3 (0–11)
Blood
eosinophils,%*
0.16 (0.05) 0.25 (0.07) 0.15 (0.04)
Values are mean (minimum-maximum).
Median (minimum-maximum).between those RA subjects who had positive methacho-
line tests and the other asthma related parameters we
examined.FEV1 and percentage reversibility
None of the RA group or the control subjects demon-
strated greater than 15% bronchodilatability assessed by
FEV1 after beta agonist administration. In contrast, 5
out of 15 asthma subjects demonstrated greater than
15% reversibility with the mean degree of reversibility
being close to 15% for the CA group as a whole (Table 1),
which was significantly greater than that of the RA sub-
jects. There was no difference in reversibility between
the RA and control groups.Serum IgE and skin test positivity
Asthmatics (CA) had a significantly greater serum IgE than
either RA or control groups. It was an objective, of our
recruiting, to try and match RA and asthma subjects as far
as possible for similar levels of “atopy” as defined by the
number of positive skin tests to common aeroallergens. At
a broad level, (atopic versus non atopic) our matching was
good; however, there was a small but significant (p< 0.05)
difference between the numbers of positive skin tests in
the RA group and the CA group (Table 1).Sputum analysis
Sputum cell analysis
The cells within the sputum can provide an important
reflection of the local inflammatory process within the
airways in asthma. The total sputum cellularity was not
significantly different between subject groups (data not
shown). The most striking and significant difference, be-
tween the subject groups, was in the eosinophil com-
partment. The CA group had >30 fold more eosinophils
than the RA group (p < 0.01) (Table 2), while there was
little evidence of differences in the proportions of neu-
trophils, macrophages, lymphocytes or bronchial epithe-
lial cells between the subject groups (Table 2). It is
notable that the sputum eosinophilia in the CA group
occurred in the absence of any significant blood eosino-
philia (Table 1).Table 2 Total and differential counts in sputum
Control CA RA
Total Cell Count (×106) 9.56±8.67 3.38±2.32 6.60±5.93
% Eosinophils 0.043±0.012 7.06±11.19 0.292±0.439
% Neutrophils 37.16±21.56 22.64±14.24 29.96±22.25
% Macrophages 68.53±22.05 65.8±19.52 61.3±21.9
% Lymphocytes 0.98±0.92 1.72±1.40 0.98±0.87
Waserman et al. Allergy, Asthma & Clinical Immunology 2012, 8:16 Page 5 of 14
http://www.aacijournal.com/content/8/1/16Sputum fibrinogen and eosinophil cationic protein (ECP)
Increased levels of sputum fibrinogen have been widely
used as a marker for airways damage and inflammation. In
this study, we observed no significant differences between
our three subject groups in terms of sputum fibrinogen
level (Figure 2A). There was a significant (p< 0.05) in-
crease in ECP in the CA group compared with the RA
group. The RA group had levels of ECP very similar to the
control group (Figure 2B). These results are consistent
with the numbers of eosinophils observed within the spu-
tum samples.Sputum IL-5 and IL-10
The cytokines IL-5 and IL-10 were selected for study in
the sputum supernatant for several reasons, including
the critical nature of these cytokines in regulating air-
ways inflammation, and the previous experience of our-
selves and others in measuring cytokines at this site.
There was a significant elevation in sputum IL-5 for
asthmatic subjects (CA) compared with control subjects
(Figure 2C). The RA group had intermediate levels of
this sputum cytokine compared with the other two
groups. In contrast, there were no substantial differences in
the levels of IL-10 between the subject groups (Figure 2D).Peripheral blood cytokines
Preliminary experiments using normal and asthmatic
(CA) subjects (data not shown) defined the optimal tim-
ing and stimulus doses required for studies of PBMC
cytokine expression. We chose to examine the produc-
tion of a number of type 1, type 2 and pro-inflammatory
cytokines without fractionation of the cells, in order toFigure 2 Sputum mediator measurements from matched triplets of R
sputum ECP, (C) sputum IL-5 (D) sputum IL-10. Each point represents in
by bars. Significant (p < 0.05) differences in mediator levels between RA and
for sputum fibrinogen or sputum IL-10.obtain a picture of the cytokine production capability of
the mixed cell population found in vivo. Our results
revealed a number of significant differences in cytokine
expression between the three subject groups.IL-12
Examination of IL-12 production at 72 h revealed
that asthmatic subjects (CA) had consistently higher
levels of IL-12 production than RA subjects or con-
trol subjects under a range of stimulation conditions
(Figure 3A). None of the activating conditions elevated
IL-12 production significantly under our culture con-
ditions, in keeping with literature reports that single
stimuli are not optimal for IL-12 induction. However,
significant differences were observed between the groups
when cells were incubated with media alone (p < 0.01) or
activated with OKT3 (p< 0.05) or LPS (p < 0.05). Similar
differences between groups were obtained when 1 L-12
production was examined at 24 h (data not shown)
although the levels of IL-12 production were lower.IFN-γ
IFN-γ is widely used as a marker for a Th-1 response in
disease models. Examination of the production of IFN-γ
in stimulated and control cultures after 24 hours revealed
some important differences between our subject groups
(Figure 3B). Both OKT3 and SAC were highly effective in
inducing IFN-γ production in all subject groups. While
there was no notable difference between asthmatic (CA)
and control subjects in terms of IFN-γ production, RA
subjects showed a striking decrease in IFN-γ production
compared with either of these groups. RA subject PBMCA, CA and control group subjects (A) sputum fibrinogen, (B)
dividual values or multiple identical values. Median values are denoted
CA groups were observed for sputum ECP and sputum IL-5 but not
Figure 3 The production of type 1 cytokines by PBMC from matched triplets of RA, CA and control subjects in response to a range of
stimuli i.e. mouse anti-human CD3 (OKT3) 1 μg/ml, LPS 1 μg/ml and heat killed S. aureus Cowan strain 1 (0.01%w/v) (SAC). (A) IL-12
production at 72 h, (B) IFN-γ production at 24 h, (C) TNF-α production at 24 h. A similar profile of results were obtained when IL-12 was
assayed at 24 h (data not shown). All supernatant samples were assayed in parallel by ELISA. Each point denotes the result from individual
supernatants or from multiple identical values. Bar denotes median value for the group. RA values were significantly lower than those in the CA
group under the following conditions: For IL-12 (A) media alone, OKT3, LPS, For IFN-γ(B) OKT3, for TNF-α (C) Media alone OKT3, LPS.
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group when cells were incubated with media alone or
with OKT3 (p < 0.05), but no such difference was
observed when cells were activated with the less physio-
logically relevant A23187+ phorbol ester.TNF-α
This cytokine is considered pivotal for the development
and maintainance of an inflammatory response. Both
lymphocytes and monocytes are recognised sources of
TNF. OKT3, SAC, LPS and PdBu +A23187 were alleffective stimuli for TNF-α production (Figure 3C). In
general the CA group produced an elevated level of
TNF-α compared with the control group. When compared
with the RA subject group, the CA group PBMC produced
significantly more TNF-α when cultured with media alone
(p< 0.02) or OKT3 (p< 0.02) or LPS (p< 0.05). The RA
subjects did not differ significantly from controls with
respect to TNF-α production.
IL-4
The levels of IL-4 produced in the PBMC cultures were
very low and close to the limit of detection unless
Figure 4 The production of type 2 cytokines and GM-CSF by PBMC in response to a range of stimuli i.e. mouse anti-human CD3
(OKT3) 1 μg/ml, LPS 1 μg/ml and heat killed S. aureus Cowan strain 1 (0.01%w/v (SAC). (A) IL-4 production at 24 h, (B) IL-5 production at
24 h, (C) IL-10 production at 24 h, (D) GM-CSF production at 24 h. No significant differences were noted between RA and CA groups for any of
these cytokines under any of the activation conditions employed.
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0.13 pg/ml, Figure 4A). However, both the CA and RA
groups, who were mainly atopic, produced significantly
more IL-4 than control (non-atopic) subjects in the
presence of OKT3. Since OKT3 is known to activate
T-cells specifically this should reflect the activated T cell
response in these subjects.IL-5
Very low or undetectable levels of IL-5 were produced
in response to most of the stimuli we employed at 24 h
(Figure 4B) although a significant response was observed
to OKT3 activation. There was a trend towards
increased IL-5 production in the asthmatic subjects
(CA) compared with the other subject groups, but it did
not reach statistical significance. We did not observe,within the PBMC, the dramatic increases in IL-5 that
were observed in the sputum of the CA subjects.
IL-10
Production of this cytokine was examined after 24 h and
72 h in culture with similar results. The data from 72 h
cultures are illustrated in Figure 4C. There was a high
level of endogenous IL-10 production in this culture sys-
tem. The production of IL-10 was significantly enhanced
in all groups of subjects by the addition of LPS and
inhibited by the addition of SAC. There were no signifi-
cant differences between CA and RA subjects under any
of the stimulation conditions used at either time point.
GM-CSF
Low, but detectable levels of GM-CSF were produced by
all subjects under most activation conditions (Figure 3D).
Blood Cell Phenotyping and Markers    
A: T cell subsets 
Whole Blood 
CD3 T cell 
Other lymph’s / mono’s 
granulocytes 
CD3 T cell 
% CD4+DR+ of CD3 % CD8+DR+ of CD3 
(Gated as CD3+ lymph’s) 
** **
Figure 5 Representative data for flow cytometry analysis of T lymphocyte subsets and their activation or differentiation markers. CD3+
T lymphocytes (top right, R2 region) were first identified from whole blood cells defined by FSC and SCC (top left, R6 region). CD3+ T
lymphocyte subsets were further defined by expression of CD4, CD8, and activation/differentiation markers such as HLA-DR (lower panels).
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induced a significant enhancement of GM-CSF produc-
tion. RA subjects produced significantly (p < 0.02) more
GM-CSF than the CA subjects or controls following
such activation.Blood Cell Phenotyping and Markers    
B: B cells and monocytes 
Whole Blood 
CD3 T cell 
Other lymph’s / mono’s 
granulocytes 
Figure 6 Representative data for flow cytometry analysis of B lympho
and CD14 monocytes (bottom right R4 region) are clearly distinguished fro
indicated by R6 in the center plot.Flow cytometric analysis of PBMC
T cell subset, B cell and monocyte frequencies
A multicolour analysis of T cell subsets, B cells and
monocytes, was performed by flow cytometry of whole
blood. The identification and analyses of various subsetsmonocytes 
B cells 
cytes and monocytes. CD19+ B lymphocytes (top right R3 region)
m all other blood cells included in WBC gate for whole blood cells as
Figure 7 Percentage of effector cells and their subsets present in blood from RA CA and control subjects, based on results of flow cytometric
analysis of whole blood. (A) percentage of lymphocytes expressing the CD3 T-cell marker. (B) the percentage of T-lymphocytes expressing CD4.
(C) the percentage of T-lyphocytes expressing CD8. (D) the percentage of lymphocytes expressing the B-cell marker CD19. (E) the percentage of
white blood cells expressing CD14. No significant differences were noted between the subject groups from any of these markers.
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were no significant differences between the three groups
of subjects for the percentage of CD3+ (total T-cells),
percentage of CD4+ or CD8+ T-cells or the percentage
of B-cells among the lymphocyte population. There were
also no differences in the percentage of monocytes
among the total leukocytes (Figure 7).
Activated and memory T-cell subsets
Representative flow cytometric data showing typical ana-
lysis of T cell subset expression of activation markersCD69 and HLA-DR and differentiation markers CD40L
and CD45RO are shown in Figure 8. CD69 expression
indicates very recent activation of T-cells. The frequency
of T cells expressing CD69 is normally very low among
blood cells and many samples had no significant CD69
staining above background (0.5%) (Figures 9A and 9B).
In contrast, examination of HLA-DR expression on
T-cells, which is used as a marker of “near recent” activa-
tion, (typically among effector memory T cells) revealed an
increase in HLA-DR expression of CD8 positive T-cells
from the CA group compared with the RA group (p<0.05)
Figure 8 Representative data illustrating analysis of T cell subsets and expression of activation and differentiation markers CD69,
CD40L, HLA-DR, CD45RO. Data are derived from normal control subject, illustrating typical frequency of cells expressing of these markers.
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subset although statistical significance was not reached
(Figure 9C). Examination of the expression of CD40
ligand by CD4+ T-cells also revealed differences between
the subject groups with a decreased frequency of CD40
ligand expressing CD4+ cells in the CA group compared
with the RA group (p< 0.05) (Figure 10A). A similar trend
was observed in the CD8+ subset but without statistical
significance.
CD45RO was used as a marker for memory/activated
T-cells. CD45RO cells are generally phenotypically recip-
rocal to CD45RA (naive) T-cells with a low percentage
of cells being positive for both markers. Neither
CD45RO nor CD45RA expression on CD4 or CD8 sub-
sets were different between the three subject groups
(data not shown).
B-cell and monocyte activation markers
The frequency of B-cells expressing CD40, CD23 and
HLA DR as well as the relative amounts (median fluor-
escence intensity) of these molecules were determined.
All three markers are expressed by nearly 100% of B-
cells in blood. In addition, the levels of expression of
each of these markers can increase on activated B-cells.
Circulating monocytes rarely express CD40 or CD23 butalmost all express HLA-DR. However, CD40 and CD23
can be expressed de novo on monocytes following activa-
tion and HLA-DR can be up-regulated following appro-
priate stimulation of monocytes. There were no
significant differences between the subject groups for
the percentages of B-cells expressing each of these mar-
kers and no differences in the level of expression for
CD40, CD23 or HLA-DR (Table 3). Similarly there was
no difference in the level of monocyte expression of
HLA-DR.
Discussion
The studies we describe here provide novel insights into
the differences between children whose asthma has
resolved spontaneously and those in which it remains
symptomatic. Increased levels of sputum eosinophils and
sputum IL-5, increased peripheral blood mononuclear
cell-derived TNF-α, IL-12, and decreased IFN-γ levels
were associated with on-going asthma symptoms and
airway hyperresponsiveness. We did not demonstrate
any clear differences in T or B cell subsets, memory cells
or activation markers between children with ongoing
asthma symptoms and those in whom symptoms had
completely resolved. However, where subtle differences
were noted between the CA and RA groups, the RA
Figure 9 The expression of activation markers on CD4 and CD8
T-cell subsets in blood from RA CA and control groups of
subjects. (A) percentage of CD69 positive CD4 positive T-cells.
(B) percentage of CD69 positive CD8 positive T-cells. (C) percentage of
HLA-DR positive CD4 positive T-cells (D) percentage of HLA-DR positive
CD8 positive T-cells. Note significant (P < 0.05) increase in HLA-DR
positive CD8 positive T-cells in CA group compared with control group.
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subjects.
Initial clinical examination revealed that many of the
asymptomatic subjects remained hyperresponsive as
defined by methacholine challenge tests. In a sample of
551 adolescent and young adult subjects Kolnaar et al.
[34] observed that 42% of subjects exhibited airways
hyper responsiveness, of which 70% were asymptomatic.
These data would suggest a slightly lower rate in the
population than our observation of hyper responsivenessFigure 10 CD40 ligand (CD40L) expression by T-cell subsets
from the blood of RA, CA and control subjects. (A) Percentage of
CD40 L positive CD4 positive T-cells (B) percentage of CD40L
positive CD8 positive T-cells. Note significant (P < 0.05) increase in
CD40L positive CD4 positive T-cells in the RA group compared with
the CA group.in 8 of 15 asymptomatic RA subjects. A much larger
study would be required to determine whether the rate
of asymptomatic AHR in RA subjects was increased
relative to the levels in the age matched general popula-
tion. Other studies in childhood [35] have suggested that
asymptomatic bronchial hyperresponsiveness, in this
case observed after allergen challenge, can predict the
development of asthma. The lack of AHR in many of the
RA subjects suggests that the AHR resolves in many
subjects in which asthma symptoms resolve. It is inter-
esting that there was no evidence of an increase in FEV1
reversibility in the RA group compared with the control
group despite the high rate of AHR.
Analysis of induced sputum provides a unique window
on the inflammatory status of the airways of the RA sub-
jects and their CA counterparts. The most striking dif-
ference observed between these groups was in the levels
of eosinophils and ECP observed. The high levels of
these markers observed in CA were expected, based on
extensive literature reports of eosinophilic airways in-
flammation associated with symptomatic asthma. Not-
ably, despite the presence of positive skin tests and AHR
in over half the RA group, both the ECP and sputum
eosinophil levels were comparable with those of non-
atopic control subjects and significantly lower than
those in the CA group. The increase in eosinophils was
highly specific, as observed in other asthmatic popula-
tions [33,36] since no alterations were noted in the per-
centages of other cell types in the sputum. The local
eosinophilia in the airways did not extend to significant
changes in peripheral blood eosinophil numbers, although
a peripheral eosinophilia has been described in some
groups of asthmatics, especially in childhood [37,38].
The levels of cytokines in the sputum supernatants
reflected the eosinophilic nature of the ongoing inflam-
matory process associated with disease. The IL-5 levelsTable 3 Analysis of peripheral blood B cells, monocytes
and their expression of CD40, CD23 and HLA-DR
Cell Marker: Group Mean% (S.D.) Ave.MdFI* (S.D.)
B cells-CD23 Control 82.6 (9.4) 83.0 (39.5)
CA 82.4(8.2) 85.6 (28.9)
RA 79.6 (10.1) 90.6 (46.7)
B cells-CD40 Control 100 50.6 (18.6)
CA 100 51.4 (15.2)
RA 1000 53.4 (14.4)
B cells-HLA-DR Control 100 975 (338)
CA 100 1035 (277)
RA 100 990 (340)
Monocytes-HLA-DR Control 83.9 (12.6) 290 (118)
CA 87.5 (12.6) 322 (120)
RA 88.1 (9.2) 286 (124)
•MdFI =median fluorescence intensity.
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with the control group. In contrast, the predominately
anti-inflammatory cytokine IL-10 was found in similar
amounts in all subject groups. This finding does not
support the concept that subjects in which asthma has
resolved have enhanced local production of IL-10 com-
pared with those in which the disease persists. The inter-
mediate levels of IL-5 and TNF-α observed in RA
subjects suggest that in some individuals elevated local
concentrations of these cytokines remain, although in
the absence of substantial eosinophilia.
The relationship between eosinophilic inflammation
and AHR in asthma is not entirely clear. In murine
models of asthma, some have shown that AHR and eo-
sinophilic inflammation can be dissociated [39-41] while
others have demonstrated a link between them via IL-5
[42-45]. Among the RA subjects, of whom 8 of 15 had
AHR in the absence of symptoms, none had substantial
levels of eosinophils in sputum, which seems to indicate
that AHR can be present in certain subjects without a
high level of eosinophilic inflammation. However, several
of the RA subjects had increased IL-5 in their sputum in
the absence of substantial eosinophilia, suggesting that
perhaps this residual IL-5 may be associated with the re-
sidual AHR.
Our observations of elevated type 1 cytokine produc-
tion by PBMC from CA subjects compared with control
subjects were surprising in the context of a disease
which is traditionally associated with inflammation
driven by type 2 cytokines. There is recent information
that supports the role of IFN-γ in normalizing asthma
symptoms in childen [46]. However, several pieces of in-
formation from the existing literature support the con-
cept of an important role for the type 1 cytokine cascade
in symptomatic asthma. In early studies [47], TNF-α was
observed as increased in the BAL fluid of subjects with
“symptomatic” rather than quiescent disease. Elevated
production of TNF-α and IFN-γ by bronchoalveolar leu-
kocytes from a series of 11 patients with allergic asthma
compared with control subjects [48]. Indeed, anti-TNF
treatment has been reported to be beneficial in a subset
of patients with severe asthma [49]. More recently, using
whole blood cultures Magnan et al. [50] observed an
overproduction of IFN-γ by CD8+ T-cells in the blood
of asthmatic subjects which was related to asthma sever-
ity and suggested a role for IL-12 in inducing this re-
sponse. Observations that IFN-γ inducing factor (IL-18)
is increased in the airways of patients with atopic asthma
support the concept that enhancing the type 1 cytokine
cascade can be associated with the development of air-
ways eosinophilia [51]. Interestingly an elevated type-1
cytokine response, in atopic subjects, has also been
implicated in studies of atopic dermatitis [52]. Add-
itional recent studies in human subjects and mice havereported the positive contribution of TH1 lymphocytes
and IFN-γ to allergic lung inflammation [53-55]. It is
also been reported that eosinophil-derived IFN-γ con-
tribute to the persistence of airway hyperresponsivness
and structural changes [56]. Differences in type 1 cyto-
kine production between asthmatic and control subjects
might be missed experimentally if either the subjects
were not withdrawn from corticosteroid therapy appro-
priately or complex stimuli such as whole bacteria were
employed. Our data suggest that results obtained using
SAC as a cytokine-inducing stimulus for PBMC does
not reflect the baseline levels of cytokine expression or
the response to more direct stimulation of the T-cell or
Toll-like receptor systems.
The CA and RA subjects did not differ substantially in
their production of any of the type 2 cytokines we mea-
sured in PBMCs. Other RA and CA groups in this study
were predominately atopic and several studies have sug-
gested that enhanced ability to produce these cytokines
reflects atopic status [57,58] rather than asthma specific-
ally. Under appropriate stimulation conditions both IL-4
and IL-5 levels were elevated in supernatants from the
CA and RA PBMC compared with the non atopic con-
trol group PBMC. This is in contrast with both IL-6
(data not shown) and IL-10 which were unchanged be-
tween groups regardless of the stimuli employed.
Flow cytometric studies of peripheral blood cells from
all of the donors revealed few consistent or significant
differences. All of the groups had similar proportions of
T-cell subtypes, B-cells and monocytes suggesting that
the changes we observed in cytokine expression were
unlikely to be due to major alterations in cell distribu-
tion. The observation of elevated HLA-DR expression
on the CD8+ ve T-cells from asthmatic subjects is con-
sistent with the concept that these cells may be an im-
portant effector cell population or a source of type 1
cytokines in asthma. The increased expression of CD40
ligand that we observed in the asthma group compared
with the control group could also relate to the presence
of elevated type 1 cytokines since IL-12 has been
demonstrated to be produced as a result of enhanced
CD40/CD40L interactions [59].
This study is a unique attempt to evaluate the differ-
ences between carefully matched atopic subjects in
whom asthma symptoms have or have not resolved. Pre-
vious studies of the immune parameters associated with
growing out of asthma have concluded that lower serum
IgE or fewer positive skin tests, male gender as well as
less severe disease increase the likelihood that asthma
will resolve spontaneously [9,10,20]. There has been
some discussion that the resolution of asthma in late
childhood/adolescence is temporary [60], although good
prospective studies have not been performed in this area.
The RA subjects examined by us have been surveyed
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none of the subjects contacted had developed symptom-
atic asthma over this time period. Strategies aimed at
the IL-5 dependent eosinophil recruitment into the air-
ways or TNF-dependent airway hyperresponsiveness
may hasten the resolution of asthma symptoms. Long-
term prospective studies of children are necessary to in-
vestigate these strategies.
In conclusion, our studies of subjects who have “grown
out” of asthma symptoms compared with those in whom
disease continued has revealed that while many of these
subjects retain some degree of AHR, there is little or no
associated airways eosinophilia. As a group, those with
continuous asthma demonstrated elevated production of
type 1 cytokines compared with RA subjects. It is well
recognised that corticosteroids are potent inhibitors of
type 1 cytokine production, although this inhibition is
temporary. The ongoing challenge is to develop new
approaches to therapy which could induce the changes
which take place during spontaneous disease remission.
Further studies of subject groups such as the RA group
we describe could provide important clues to this critical
process.
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